Patent US5861248A successfully refreshed from Google Patents.
US5861248A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biomarkers for detection of prostate cancer
Assignee: Urocor Inc
•
Filing: 1996-03-29
•
Granted: 1999-01-19
•
Expires: 2016-03-29
Abstract
Abstract Disclosed are diagnostic techniques for the detection of human prostate cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate cancer compared to normal human prostate or benign prostatic hyperplasia.
Inventors
- 👤 David W. Russell
- 👤 Anice E. Thigpen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 18:56
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6876; C12Q1/6883; C12Q1/6886; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; A; A61; A61K; A61K48/00; C12Q2600/00; C12Q2600/112
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
30 words
An isolated nucleic acid segment comprising the contiguous, full-length sequence of or a sequence fully complementary to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:7.
Claim 2
Dependent Claim
30 words
An isolated nucleic acid segment comprising the contiguous, full-length sequence of or a sequence fully complementary to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:7.
Claim 3
Dependent Claim
26 words
The isolated nucleic acid segment of claim 1, further defined as comprising the contiguous, full-length sequence of or a sequence fully complementary to SEQ ID NO:1.
Claim 4
Dependent Claim
26 words
The isolated nucleic acid segment of claim 1, further defined as comprising the contiguous, full-length sequence of or a sequence fully complementary to SEQ ID NO:3.
Claim 5
Dependent Claim
26 words
The isolated nucleic acid segment of claim 1, further defined as comprising the contiguous, full-length sequence of or a sequence fully complementary to SEQ ID NO:4.
Claim 6
Dependent Claim
26 words
The isolated nucleic acid segment of claim 1, further defined as comprising the contiguous, full-length sequence of or a sequence fully complementary to SEQ ID NO:7.
Claim 7
Dependent Claim
36 words
An isolated nucleic acid segment comprising between 20 and about 100 contiguous bases from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:7 or a fully complementary sequence of the same length.
Claim 8
Dependent Claim
36 words
An isolated nucleic acid segment comprising between 20 and about 100 contiguous bases from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:7 or a fully complementary sequence of the same length.
Claim 9
Dependent Claim
68 words
A formulation comprising: (a) an oligonucleotide pair, wherein said pair is effective to prime the polymerase chain reaction amplification of a nucleic acid segment comprising a sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:7, wherein said formulation is used to detect prostate cancer cells in a biological sample; and (b) a container for each oligonucleotide in said pair.
Claim 10
Dependent Claim
68 words
A formulation comprising: (a) an oligonucleotide pair, wherein said pair is effective to prime the polymerase chain reaction amplification of a nucleic acid segment comprising a sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:7, wherein said formulation is used to detect prostate cancer cells in a biological sample; and (b) a container for each oligonucleotide in said pair.
Claim 11
Dependent Claim
58 words
A formulation comprising: (a) an oligonucleotide probe which hybridizes under high stringency conditions to a nucleic acid segment of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:7, wherein said formulation is used to detect prostate cancer cells in a biological sample; and (b) a container for storage of said probe.
Claim 12
Dependent Claim
58 words
A formulation comprising: (a) an oligonucleotide probe which hybridizes under high stringency conditions to a nucleic acid segment of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:7, wherein said formulation is used to detect prostate cancer cells in a biological sample; and (b) a container for storage of said probe.
Claim 13
Dependent Claim
37 words
A formulation comprising: (a) the oligonucleotide of SEQ ID NO:12 or SEQ ID NO:13 wherein said formulation is used to detect prostate cancer cells in a biological sample, and (b) a container for storage of said oligonucleotide.
Claim 14
Dependent Claim
37 words
A formulation comprising: (a) the oligonucleotide of SEQ ID NO:12 or SEQ ID NO:13 wherein said formulation is used to detect prostate cancer cells in a biological sample, and (b) a container for storage of said oligonucleotide.
Claim 15
Dependent Claim
15 words
The formulation of claim 9, wherein said oligonucleotide is the oligonucleotide of SEQ ID NO:12.
Claim 16
Dependent Claim
15 words
The formulation of claim 9, wherein said oligonucleotide is the oligonucleotide of SEQ ID NO:13.
Claim 17
Dependent Claim
30 words
A formulation comprising the oligonucleotide pair of SEQ ID NO:12 and SEQ ID NO:13 wherein said formulation is used in the detection of prostate cancer cells in a biological sample.
Claim 18
Dependent Claim
30 words
A formulation comprising the oligonucleotide pair of SEQ ID NO:12 and SEQ ID NO:13 wherein said formulation is used in the detection of prostate cancer cells in a biological sample.
Claim 19
Dependent Claim
14 words
The formulation of claim 12, wherein said detection is by polymerase chain reaction amplification.
Claim 20
Dependent Claim
64 words
A formulation for use in detecting prostate cancer cells in a biological sample, comprising: (a) an oligonucleotide pair, wherein each oligonucleotide of said pair is at least thirty bases long, wherein said pair is effective to prime the polymerase chain reaction amplification of a nucleic acid segment comprising a sequence of SEQ ID NO:5; and (b) a container for each oligonucleotide in said pair.
Claim 21
Dependent Claim
64 words
A formulation for use in detecting prostate cancer cells in a biological sample, comprising: (a) an oligonucleotide pair, wherein each oligonucleotide of said pair is at least thirty bases long, wherein said pair is effective to prime the polymerase chain reaction amplification of a nucleic acid segment comprising a sequence of SEQ ID NO:5; and (b) a container for each oligonucleotide in said pair.
Claim 22
Dependent Claim
52 words
A formulation comprising: (a) an oligonucleotide probe of at least 30 bases in length which hybridizes under high stringency conditions to a nucleic acid segment of SEQ ID NO:5, wherein said formulation is used to detect prostate cancer cells in a biological sample; and (b) a container for storage of said probe.
Claim 23
Dependent Claim
52 words
A formulation comprising: (a) an oligonucleotide probe of at least 30 bases in length which hybridizes under high stringency conditions to a nucleic acid segment of SEQ ID NO:5, wherein said formulation is used to detect prostate cancer cells in a biological sample; and (b) a container for storage of said probe.
References Cited (Backward Citations)
EP0186522A1
Cited
US4800159A
Cited
US5089386A
Cited
US5043272A
Cited
US5312733A
Cited
US5262311A
Cited
WO1994010343A1
Cited
US5527884A
Cited
WO1995021944A1
Cited
WO1996002002A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-01-18 | 2002-07-20 | 2003-01-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-01-18 | 2006-07-20 | 2007-01-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-01-18 | 2010-07-20 | 2011-01-19 | $7700.00 | Window Closed / Lapsed |